<2> Medtronic Diabetes Unit MiniMed Seeks $784 Million in US IPO
Medtronic’s diabetes unit, MiniMed, is set to raise $784 million in its US initial public offering (IPO), as the company seeks to tap into the growing demand for diabetes management solutions.
Background
Medtronic, a leading medical technology company, has been a major player in the diabetes management market for decades. The company’s MiniMed unit offers a range of products, including insulin pumps, continuous glucose monitors, and software solutions. With the rise of diabetes cases worldwide, Medtronic’s MiniMed unit has seen significant growth in recent years.
Market Opportunity
The global diabetes market is expected to reach $83.4 billion by 2025, growing at a CAGR of 8.4% from 2020 to 2025. The increasing prevalence of diabetes, coupled with the growing demand for innovative diabetes management solutions, presents a significant opportunity for Medtronic’s MiniMed unit.
Competitive Landscape
The diabetes management market is highly competitive, with several major players, including Sanofi, Novo Nordisk, and Eli Lilly.